Clinical trials: Cancer-related Pain
Bone Metastasis, Cancer Pain
Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
The purpose of this study is to determine whether tanezumab is effective in the treatment of cancer pain due to bone metastasis in patients already taking background opioid therapy.
- Trial name
- NCT02609828
- Testing
- Tanezumab
- Where
- 89 sites in Argentina, Australia and 14 more
- Volunteers
- 156 people
- Sponsor
- Pfizer
Liver Cancer, Pancreas Cancer
A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain
A prospective, multicenter, self-control clinical trial aim to enroll 110 patients suffered from upper abdominal (liver, pancreas, stomach, etc.) cancers .
- Conditions
- Liver Cancer, Pancreas Cancer, Stomach Cancer, Bile Duct Cancer
- Trial name
- NCT04014478
- Testing
- Endovascular Denervation
- Volunteers
- 110 people
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Painful Bone Metastases, Breast Carcinoma
MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases
This study will evaluate treatment with High Intensity Focused Ultrasound (HIFU)in combination with ThermoDox (liposomal doxorubicin) is safe and effective in reducing pain for patients with painful bone metastases.
- Conditions
- Painful Bone Metastases, Breast Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT01640847
- Testing
- High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox
- Sponsor
- Imunon
Pain
Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain
The purpose of this study is to evaluate the effectiveness and safety of Osmotic Release Oral System (OROS) hydromorphone using standardized conversion from prior opioid therapy among participants with cancer pain.
- Trial name
- NCT01648699
- Testing
- Osmotic Release Oral System (OROS) hydromorphone
- Volunteers
- 20 people
- Sponsor
- Janssen Pharmaceutica
Cancer Pain
35kDa Hyaluronan Fragment Treatment of Colorectal and Rectal Cancer
HA35 (Bioactive HA or B-HA or HA35) have good tissue permeability (B-HA injection, Ministry of Health, Registration number L20200708MP07707).
- Trial name
- NCT06209970
- Testing
- HA35
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Nakhia Impex LLC
Cancer Pain
Unique Treatment of Oncology Pain in Advanced Cancer
This will be a proof-of-concept, single arm study with a maximum of 20 patients to evaluate preliminary analgesic efficacy and safety of Trichomylin® in patients with advanced cancer (male and female) who suffer from moderate to…
- Trial name
- UTOPIA-1 (NCT06533657)
- Testing
- Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)
- Where
- 3 sites in Canada
- Volunteers
- 11 people
- Sponsor
- ZYUS Life Sciences Inc.
Bone Cancer, Bone Metastases
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
The goal of this study is to collect comparative data on safety and efficacy of MR Guided Focused Ultrasound and External Beam Radiation for treatment of metastatic bone tumors or multiple myeloma.
- Conditions
- Bone Cancer, Bone Metastases, Pain
- Trial name
- NCT01091883
- Testing
- Exablate treatment, Radiation
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- InSightec
Tumor, Pain
A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine
The purpose of this study will be to determine whether tapentadol (CG5503) is effective and safe in the treatment of chronic tumor related pain compared to placebo.
- Trial name
- NCT00472303
- Testing
- Tapentadol Extended Release, Morphine Sulphate Controlled Release
- Where
- 71 sites in Austria, Bulgaria and 14 more
- Volunteers
- 622 people
- Sponsor
- Grünenthal GmbH
Opioid-Induced Constipation
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC) in adults taking opioid therapy for chronic non-cancer pain.
- Trial name
- NCT01901302
- Testing
- CB-5945
- Volunteers
- 61 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cancer Pain
An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.
The purpose of this study is to compare of difference in NRS scores from baseline to the completion of treatment (5 days) in patients with administration of morphine sulfate versus oxycodone hydrochloride.
- Trial name
- SWITCH (NCT02660229)
- Testing
- Oxycodone Hydrochloride, Morphine Sulphate
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Mundipharma Korea Ltd
Intractable Pain, Neoplasms
NP2 Enkephalin For Treatment of Intractable Cancer Pain
The purpose of this study is to examine the impact of intradermal delivery of NP2 on pain scores and pain medication usage in subjects with intractable pain due to malignant disease.
- Trial name
- NCT01291901
- Testing
- NP2
- Where
- 18 sites in United States
- Volunteers
- 33 people
- Sponsor
- Diamyd Inc
Chronic Pain
Efficacy and Safety Study of Fentanyl Transdermal Patch for Treatment of Chronic Pain
The purpose of this study is to confirm effectiveness and safety of fentanyl transdermal patch Durogesic® D-Trans for treatment of chronic pain in participants with chronic non-cancer pain.
- Trial name
- NCT01902524
- Testing
- Fentanyl-TTS
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Janssen Korea, Ltd., Korea
Cancer Related Pain (Breakthrough Pain)
A Comparative Study of KW-2246
This is a placebo-controlled, double blind, comparative study to evaluate the efficacy and safety of KW-2246 as rescue medication at an optimal dose, which is determined by dose titration in treating breakthrough pain episodes in…
- Trial name
- 2246-004 (NCT01326689)
- Testing
- KW-2246
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Neoplasms
A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants
The purpose of this study is to evaluate the conversion rate based on the number of participants achieving pain control and safety within 1 week after switching the opioid (morphine-like medications) analgesics (drug used to…
- Trial name
- NCT01309386
- Testing
- Tapentadol ER, Morphine SR
- Where
- 22 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Janssen Pharmaceutical K.K.
Opioid-Induced Constipation (OIC)
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain, including those patients that have inadequate response to laxative…
- Trial name
- NCT01309841
- Testing
- NKTR-118
- Where
- 117 sites in United States, Australia and 2 more
- Volunteers
- 652 people
- Sponsor
- AstraZeneca
Chronic Pain, Cancer Pain
Prometra Post-Approval Study
The Prometra Pump is approved by the FDA for use in the United States. The purpose of this study is to collect long-term safety data on the Prometra Pump.
- Conditions
- Chronic Pain, Cancer Pain, Intractable Pain, Back Pain
- Trial name
- NCT01854229
- Testing
- Prometra Programmable Intrathecal Infusion Pump
- Where
- 26 sites in United States
- Volunteers
- 400 people
- Sponsor
- Flowonix Medical
Breakthrough Pain
Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
In cancer patients, pain is one of the most common symptoms. The range of reported prevalence of pain varies from 33% to 64% including different stages of cancer, during or after anticancer treatment.
- Trial name
- CAVIDIOM (NCT03435120)
- Testing
- No intervention
- Where
- 14 sites in Spain
- Volunteers
- 118 people
- Sponsor
- Angelini Farmacéutica
Cancer
A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients
Objectives: To prove non-inferiority of Targin compared to Oxycontin in terms of change of pain intensity 1. Primary objective: Change of pain intensity (NRS 0-10) score (average pain over 24 hours obtained each evening) within 4…
- Trial name
- TOP (NCT01313780)
- Testing
- Oxycodone/Naloxone, Oxycodone(single compound)
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Mundipharma Korea Ltd
Pain, Intractable, Pain Cancer
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
This is a Phase 3 study to assess the safety and efficacy of a single epidural administration of Resiniferatoxin versus standard of care for the treatment of intractable pain associated with cancer.
- Trial name
- NCT04572776
- Testing
- Resiniferatoxin, Standard of Care
- Sponsor
- Sorrento Therapeutics, Inc.
Pain, Analgesics, Opioid
A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain
The purpose of this study was to characterize the steady-state pharmacokinetic (metabolism and action) profile of OROS hydromorphone HCI (slow release) in patients who required opioid therapy on a daily basis for chronic pain…
- Trial name
- NCT00410878
- Testing
- OROS Hydromorphone HCI (slow release)
- Volunteers
- 22 people
- Sponsor
- Alza Corporation, DE, USA